pamidronate has been researched along with Jaw Diseases in 70 studies
Jaw Diseases: Diseases involving the JAW.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 9.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 7.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 7.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 7.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 5.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "Of 73 patients, 68 (93%) were treated with pamidronate or zoledronate; 69 (94%) patients suffered from malignant diseases, 3 (5%) had osteoporosis, and 1 (1%) had Paget's disease." | 4.83 | [Bisphosphonate-associated osteonecrosis of the jaw]. ( Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T, 2006) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 3.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 3.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 3.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| " We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively." | 3.73 | [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis]. ( Gregersen, H; Neumann, B, 2006) |
| " Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures." | 3.73 | [Osteonecrosis associated with the use of biphosphonates: Case report]. ( Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I, 2006) |
| " The preliminary results seem to suggest that biphosphonate-associated osteonecrosis can be well controlled by a nonsurgical protocol consisting in long-term administration of antibiotics." | 2.73 | Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. ( Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A, 2007) |
| "Pamidronate appears to be an effective and well-tolerated therapeutic option for patients with fibrous dysplasia." | 2.71 | Treatment of monostotic fibrous dysplasia with pamidronate. ( Godzinski, J; Klempous, J; Kos, M; Luczak, K, 2004) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "Using the Pmetrics package and published data, we designed a population pharmacokinetic model of pamidronate concentration in plasma and bone and derived a toxic bone BP threshold of 0." | 1.39 | Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. ( Jelliffe, RW; Jones, AC; Kiss, A; LaVallee, C; Le, AD; Lee, P; Neely, M; Sedghizadeh, PP, 2013) |
| "In this cohort study, patients with multiple myeloma (MM) on intravenous BP therapy were enrolled over 1 year." | 1.37 | Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. ( Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D, 2011) |
| "Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables." | 1.35 | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009) |
| "In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ." | 1.35 | Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. ( Dodson, TB; Wessel, JH; Zavras, AI, 2008) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "Multiple myeloma was the most common comorbidity." | 1.34 | Bisphosphonates and jaw osteonecrosis: the UAMS experience. ( Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient." | 1.33 | Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (74.29) | 29.6817 |
| 2010's | 18 (25.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Souza Tolentino, E | 1 |
| de Castro, TF | 1 |
| Michellon, FC | 1 |
| Passoni, ACC | 1 |
| Ortega, LJA | 1 |
| Iwaki, LCV | 1 |
| da Silva, MC | 1 |
| Owosho, AA | 1 |
| Liang, STY | 1 |
| Sax, AZ | 1 |
| Wu, K | 1 |
| Yom, SK | 1 |
| Huryn, JM | 1 |
| Estilo, CL | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| La Verde, N | 1 |
| Bareggi, C | 1 |
| Garassino, M | 1 |
| Borgonovo, K | 1 |
| Sburlati, P | 1 |
| Pedretti, D | 1 |
| Bianchi, C | 1 |
| Perrone, S | 1 |
| Mihali, D | 1 |
| Cobelli, S | 1 |
| Mantica, C | 1 |
| Rizzo, A | 1 |
| Farina, G | 1 |
| Chahine, C | 1 |
| Cheung, MS | 1 |
| Head, TW | 1 |
| Schwartz, S | 1 |
| Glorieux, FH | 1 |
| Rauch, F | 1 |
| Alons, K | 1 |
| Kuijpers, SC | 1 |
| de Jong, E | 1 |
| van Merkesteyn, JP | 1 |
| Geusens, P | 1 |
| Lazarovici, TS | 1 |
| Yahalom, R | 1 |
| Taicher, S | 1 |
| Elad, S | 1 |
| Hardan, I | 1 |
| Yarom, N | 1 |
| Stanton, DC | 1 |
| Balasanian, E | 1 |
| Stockmann, P | 2 |
| Hinkmann, FM | 1 |
| Lell, MM | 1 |
| Fenner, M | 1 |
| Vairaktaris, E | 1 |
| Neukam, FW | 1 |
| Nkenke, E | 2 |
| O'Ryan, FS | 1 |
| Khoury, S | 1 |
| Liao, W | 1 |
| Han, MM | 1 |
| Hui, RL | 1 |
| Baer, D | 1 |
| Martin, D | 1 |
| Liberty, D | 1 |
| Lo, JC | 1 |
| Hoefert, S | 1 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 1 |
| Vahtsevanos, K | 2 |
| Kyrgidis, A | 1 |
| Verrou, E | 2 |
| Katodritou, E | 1 |
| Triaridis, S | 1 |
| Andreadis, CG | 1 |
| Boukovinas, I | 1 |
| Koloutsos, GE | 1 |
| Teleioudis, Z | 2 |
| Kitikidou, K | 1 |
| Paraskevopoulos, P | 1 |
| Zervas, K | 2 |
| Antoniades, K | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Scoletta, M | 1 |
| Arduino, PG | 1 |
| Dalmasso, P | 1 |
| Broccoletti, R | 1 |
| Mozzati, M | 1 |
| Ficarra, G | 1 |
| Beninati, F | 1 |
| López-Jornet, P | 2 |
| Camacho-Alonso, F | 2 |
| Molina-Miñano, F | 2 |
| Gómez-García, F | 2 |
| Vicente-Ortega, V | 2 |
| Gimsing, P | 1 |
| Carlson, K | 1 |
| Turesson, I | 1 |
| Fayers, P | 1 |
| Waage, A | 1 |
| Vangsted, A | 1 |
| Mylin, A | 1 |
| Gluud, C | 1 |
| Juliusson, G | 1 |
| Gregersen, H | 2 |
| Hjorth-Hansen, H | 1 |
| Nesthus, I | 1 |
| Dahl, IM | 1 |
| Westin, J | 1 |
| Nielsen, JL | 1 |
| Knudsen, LM | 1 |
| Ahlberg, L | 1 |
| Hjorth, M | 1 |
| Abildgaard, N | 1 |
| Andersen, NF | 1 |
| Linder, O | 1 |
| Wisløff, F | 1 |
| Wehrhan, F | 1 |
| Hyckel, P | 1 |
| Amann, K | 1 |
| Ries, J | 1 |
| Schlegel, K | 1 |
| Neukam, F | 1 |
| Katz, J | 1 |
| Gong, Y | 1 |
| Salmasinia, D | 1 |
| Hou, W | 1 |
| Burkley, B | 1 |
| Ferreira, P | 1 |
| Casanova, O | 1 |
| Langaee, TY | 1 |
| Moreb, JS | 1 |
| Nicolatou-Galitis, O | 1 |
| Papadopoulou, E | 1 |
| Sarri, T | 1 |
| Boziari, P | 1 |
| Karayianni, A | 1 |
| Kyrtsonis, MC | 1 |
| Repousis, P | 1 |
| Barbounis, V | 1 |
| Migliorati, CA | 1 |
| Ngamphaiboon, N | 1 |
| Frustino, JL | 1 |
| Kossoff, EB | 1 |
| Sullivan, MA | 1 |
| O'Connor, TL | 1 |
| Martínez-Canovas, A | 1 |
| Cella, L | 1 |
| Oppici, A | 1 |
| Arbasi, M | 1 |
| Moretto, M | 1 |
| Piepoli, M | 1 |
| Vallisa, D | 1 |
| Zangrandi, A | 1 |
| Di Nunzio, C | 1 |
| Cavanna, L | 1 |
| Mawardi, H | 1 |
| Giro, G | 1 |
| Kajiya, M | 1 |
| Ohta, K | 1 |
| Almazrooa, S | 1 |
| Alshwaimi, E | 1 |
| Woo, SB | 2 |
| Nishimura, I | 1 |
| Kawai, T | 1 |
| Bartl, R | 1 |
| Thumbigere-Math, V | 1 |
| Tu, L | 1 |
| Huckabay, S | 1 |
| Dudek, AZ | 1 |
| Lunos, S | 1 |
| Basi, DL | 1 |
| Hughes, PJ | 1 |
| Leach, JW | 1 |
| Swenson, KK | 1 |
| Gopalakrishnan, R | 1 |
| Sedghizadeh, PP | 1 |
| Jones, AC | 1 |
| LaVallee, C | 1 |
| Jelliffe, RW | 1 |
| Le, AD | 1 |
| Lee, P | 1 |
| Kiss, A | 1 |
| Neely, M | 1 |
| Marx, RE | 2 |
| Tarassoff, P | 1 |
| Csermak, K | 1 |
| Kos, M | 1 |
| Luczak, K | 1 |
| Godzinski, J | 1 |
| Klempous, J | 1 |
| Carter, GD | 1 |
| Goss, AN | 1 |
| Greenberg, MS | 1 |
| Jimenez-Soriano, Y | 1 |
| Bagan, JV | 1 |
| Durie, BG | 1 |
| Katz, M | 1 |
| Crowley, J | 1 |
| Hande, K | 1 |
| Richardson, PG | 1 |
| Sarathy, AP | 1 |
| Bourgeois, SL | 1 |
| Goodell, GG | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Terpos, E | 2 |
| Dimopoulos, MA | 1 |
| Abi Najm, S | 1 |
| Lysitsa, S | 1 |
| Carrel, JP | 1 |
| Lesclous, P | 1 |
| Lombardi, T | 1 |
| Samson, J | 1 |
| Pastor-Zuazaga, D | 1 |
| Garatea-Crelgo, J | 1 |
| Martino-Gorbea, R | 1 |
| Etayo-Pérez, A | 1 |
| Sebastián-López, C | 1 |
| Abu-Id, MH | 2 |
| Açil, Y | 2 |
| Gottschalk, J | 2 |
| Kreusch, T | 2 |
| Alexander, RE | 1 |
| Farrar, SK | 1 |
| Thakkar, SG | 1 |
| Isada, C | 1 |
| Smith, J | 1 |
| Karam, MA | 1 |
| Reed, J | 1 |
| Tomford, JW | 1 |
| Englund, K | 1 |
| Richmond, M | 1 |
| Licata, A | 1 |
| Hatch, C | 1 |
| Hussein, MA | 1 |
| Dimitrakopoulos, I | 1 |
| Magopoulos, C | 1 |
| Karakasis, D | 1 |
| Neumann, B | 1 |
| Banti, A | 1 |
| Mihou, D | 1 |
| Krikelis, D | 1 |
| Weeda, LW | 1 |
| Kademani, D | 1 |
| Koka, S | 1 |
| Lacy, MQ | 1 |
| Rajkumar, SV | 1 |
| Wutzl, A | 1 |
| Eisenmenger, G | 1 |
| Hoffmann, M | 1 |
| Czerny, C | 1 |
| Moser, D | 1 |
| Pietschmann, P | 1 |
| Ewers, R | 1 |
| Baumann, A | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Anguita C, T | 1 |
| Agurto P, J | 1 |
| Roa E, I | 1 |
| Laissle C, G | 1 |
| Merigo, E | 1 |
| Manfredi, M | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Vescovi, P | 1 |
| Dannemann, C | 1 |
| Grätz, KW | 1 |
| Riener, MO | 1 |
| Zwahlen, RA | 1 |
| Clarke, BM | 1 |
| Boyette, J | 1 |
| Vural, E | 1 |
| Suen, JY | 1 |
| Anaissie, EJ | 1 |
| Stack, BC | 1 |
| Corso, A | 1 |
| Varettoni, M | 1 |
| Zappasodi, P | 1 |
| Klersy, C | 1 |
| Mangiacavalli, S | 1 |
| Pica, G | 1 |
| Lazzarino, M | 1 |
| Montebugnoli, L | 1 |
| Felicetti, L | 1 |
| Gissi, DB | 1 |
| Pizzigallo, A | 1 |
| Pelliccioni, GA | 1 |
| Marchetti, C | 1 |
| Shenker, NG | 1 |
| Jawad, AS | 1 |
| Jadu, F | 1 |
| Lee, L | 1 |
| Pharoah, M | 1 |
| Reece, D | 1 |
| Wang, L | 1 |
| Brown, JJ | 1 |
| Ramalingam, L | 1 |
| Zacharin, MR | 1 |
| Warnke, PH | 1 |
| Springer, I | 1 |
| Wiltfang, J | 1 |
| Russo, PA | 1 |
| Bianchi, ML | 1 |
| Limonta, C | 1 |
| Frasunkiewicz, J | 1 |
| Biggioggero, M | 1 |
| Vai, S | 1 |
| Bedogni, A | 1 |
| Blandamura, S | 1 |
| Lokmic, Z | 1 |
| Palumbo, C | 1 |
| Ragazzo, M | 1 |
| Ferrari, F | 1 |
| Tregnaghi, A | 1 |
| Pietrogrande, F | 1 |
| Procopio, O | 1 |
| Saia, G | 1 |
| Ferretti, M | 1 |
| Bedogni, G | 1 |
| Chiarini, L | 1 |
| Ferronato, G | 1 |
| Ninfo, V | 1 |
| Lo Russo, L | 1 |
| Lo Muzio, L | 1 |
| Nocini, PF | 1 |
| Kohno, N | 1 |
| Wessel, JH | 1 |
| Dodson, TB | 1 |
| Zavras, AI | 1 |
| Sari, E | 1 |
| Bulut, N | 1 |
| Altundag, K | 1 |
| Landesberg, R | 1 |
| Cozin, M | 1 |
| Cremers, S | 1 |
| Woo, V | 1 |
| Kousteni, S | 1 |
| Sinha, S | 1 |
| Garrett-Sinha, L | 1 |
| Raghavan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.[NCT00376883] | Phase 3 | 500 participants | Interventional | 2000-01-31 | Completed | ||
| Development Of A Predictive Score For Maxillary Osteochimionecrosis After Invasive Oral Surgery In Patients Treated Whith Biphosphonates Or Biotherapies: The PREV-ONM Study[NCT04257721] | 45 participants (Actual) | Observational | 2019-10-10 | Terminated (stopped due to rate of inclusions too low) | |||
| Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers[NCT04584840] | 50 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pamidronate and Jaw Diseases
| Article | Year |
|---|---|
Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservati | 2019 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injectio | 2007 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Im | 2006 |
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2008 |
4 trials available for pamidronate and Jaw Diseases
| Article | Year |
|---|---|
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow- | 2010 |
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2010 |
Treatment of monostotic fibrous dysplasia with pamidronate.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Diphosphonates; Facial Pain; Female; Fibr | 2004 |
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bo | 2007 |
61 other studies available for pamidronate and Jaw Diseases
| Article | Year |
|---|---|
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Ja | 2018 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femal | 2008 |
Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Female; Follow | 2008 |
Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bac | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Femal | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni | 2010 |
An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats.
Topics: Animals; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Drug Combinations; Glucoco | 2010 |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogen | 2011 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collag | 2011 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Co | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti | 2011 |
Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bone Density Conservation Agents; Dexamethas | 2011 |
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.
Topics: Aged; Diphosphonates; Female; Humans; Injections, Intralesional; Jaw Diseases; Osteonecrosis; Osteop | 2011 |
A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cell Sur | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, | 2012 |
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone De | 2013 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecros | 2003 |
Bisphosphonates and avascular necrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zole | 2003 |
Intravenous bisphosphonates and osteonecrosis.
Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Di | 2004 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Int | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
[Bisphosphonates-related jaw osteonecrosis].
Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Human | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce | 2006 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; D | 2006 |
The buzz about bisphosphonates.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Midd | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mult | 2006 |
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Jaw Diseases; Male; M | 2006 |
Drug induced osteonecrosis of the jaws.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Densit | 2006 |
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazole | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fol | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonec | 2006 |
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Disea | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Inc | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteopo | 2007 |
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
Topics: Diphosphonates; Humans; Incidence; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Radio | 2007 |
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazo | 2008 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphona | 2008 |
Comment on: Bisphosphonates and osteonecrosis of the jaw.
Topics: Administration, Oral; Adolescent; Adult; Alendronate; Child; Child, Preschool; Diphosphonates; Dose- | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphospho | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Co | 2008 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Dis | 2008 |
Inhibition of oral mucosal cell wound healing by bisphosphonates.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Proliferation; Cells, Cultured | 2008 |